Amarantus will only own 50% shares pre capital raise. The capital raise to uplist will dilute the shares thereby reducing AMBS % ownership. Regardless, AMBS will end up a major share holder in a Nasdaq listed company that will have the necessary resources to develop its assets.
(1)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links